MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...
22mon MSN
Ahead of National Signing Day, several of the top programs in the country are expected to make one final run at the remaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback